Compare XTNT & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XTNT | NSRX |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 37.1M |
| IPO Year | 2009 | 2024 |
| Metric | XTNT | NSRX |
|---|---|---|
| Price | $0.21 | $2.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | $0.75 | ★ $16.50 |
| AVG Volume (30 Days) | ★ 226.9K | 11.6K |
| Earning Date | 11-16-2026 | 08-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 125.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $53,337,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.17 | $1.98 |
| 52 Week High | $0.84 | $9.50 |
| Indicator | XTNT | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.58 | 25.53 |
| Support Level | N/A | $2.04 |
| Resistance Level | $0.47 | $3.61 |
| Average True Range (ATR) | 0.03 | 0.21 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 26.33 | 3.35 |
Xtant Medical Holdings Inc is a medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. The company's biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect Plus DBM putty, OsteoWrap, and the line of 3Demin products, as well as other allografts. It generates a majority of its revenue from the U.S.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.